FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Matthias Kassack

Research Profile

Chemicals & Drugs

Anatomy

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Living Beings

Phenomena

Protein Binding

Co-author Network

Publications

TOP 3
Weaam Ebrahim; François Gaascht; Matthias U Kassack; Tibor Kurtan; Wenhan Lin; Attila Mándi; Barbora Orlikova; Amal H Aly; Abdessamad Debbab; Marc Diederich; Marie-Hélène Teiten; Victor Wray; Peter Proksch
Embellicines A and B: absolute configuration and NF-κB transcriptional inhibitory activity.
Elisabeth Christiansen; Maria E Due-Hansen; Manuel Grundmann; Ellen Hagesaether; Steffen V F Hansen; Brian D Hudson; Matthias U Kassack; Evi Kostenis; Stine B Markussen; Graeme Milligan; Johannes Schmidt; Christian Urban; Mohamed Zaibi; Michael A Cawthorne; Trond Ulven
Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Linda Marek; Holger Gohlke; Alexandra Hamacher; Finn K Hansen; Matthias U Kassack; Krystina Kuna; Thomas Kurz
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Matthias Kassack (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Weaam Ebrahim; François Gaascht; Matthias U Kassack; Tibor Kurtan; Wenhan Lin; Attila Mándi; Barbora Orlikova; Amal H Aly; Abdessamad Debbab; Marc Diederich; Marie-Hélène Teiten; Victor Wray; Peter Proksch
Embellicines A and B: absolute configuration and NF-κB transcriptional inhibitory activity.
Journal of medicinal chemistry 2013;56(7):2991-9.
2013: Elisabeth Christiansen; Maria E Due-Hansen; Manuel Grundmann; Ellen Hagesaether; Steffen V F Hansen; Brian D Hudson; Matthias U Kassack; Evi Kostenis; Stine B Markussen; Graeme Milligan; Johannes Schmidt; Christian Urban; Mohamed Zaibi; Michael A Cawthorne; Trond Ulven
Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Journal of medicinal chemistry 2013;56(3):982-92.
2013: Linda Marek; Holger Gohlke; Alexandra Hamacher; Finn K Hansen; Matthias U Kassack; Krystina Kuna; Thomas Kurz
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
Journal of medicinal chemistry 2013;56(2):427-36.
2013: Ralf Hausmann; Matthias U Kassack; Achim Kless; Daniel Kuhlmann; Fritz Markwardt; Gregor Bahrenberg; Janka Günther; Günther Schmalzing
Salt bridge switching from Arg290/Glu167 to Arg290/ATP promotes the closed-to-open transition of the P2X2 receptor.
Molecular pharmacology 2013;83(1):73-84.
2012: Elisabeth Christiansen; Maria E Due-Hansen; Manuel Grundmann; Brian D Hudson; Matthias U Kassack; Evi Kostenis; Graeme Milligan; Ralf Schröder; Michael A Cawthorne; Christian Urban; Trond Ulven
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
Journal of medicinal chemistry 2012;55(14):6624-8.
2012: Beate Wollinsky; Xia Yu; Alexandra Hamacher; Matthias U Kassack; Lena Ludwig; Shu-Ming Li
Prenylation at the indole ring leads to a significant increase of cytotoxicity of tryptophan-containing cyclic dipeptides.
Bioorganic & medicinal chemistry letters 2012;22(12):3866-9.
2012: Maria Thereza Cargnelutti; Daniel Esser; Matthias U Kassack; Adriana Fonseca Marques; Robson Q Monteiro; Luis Mauricio T R Lima
Allosteric activation of human α-thrombin through exosite 2 by suramin analogs.
Archives of biochemistry and biophysics 2012;520(1):36-41.
2011: Elisabeth Christiansen; Maria E Due-Hansen; Manuel Grundmann; Ellen Hagesaether; Matthias U Kassack; Evi Kostenis; Leonardo Pardo; Johannes Schmidt; Susanne Ullrich; Christian Urban; Trond Ulven
Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
Journal of medicinal chemistry 2011;54(19):6691-703.
2011: Corinna Wetzel; Wim Watjen; Philip Böhler; Alexandra Hamacher; Matthias U Kassack; Peter C Kunz; Ingo Ott; Riccardo Rubbiani; Bernhard Spingler
Gold(I) complexes of water-soluble diphos-type ligands: synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition.
Dalton transactions (Cambridge, England : 2003) 2011;40(36):9212-20.
2011: Sherif Saeed Ebada Elsayed; Alexandra Hamacher; Matthias U Kassack; Michael H G Kubbutat; Wenhan Lin; Werner E G Müller; Barbara Schulz; Frank Totzke; Victor Wray; Peter Proksch
Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.
Bioorganic & medicinal chemistry 2011;19(15):4644-51.
2011: Christian Wolf; Christiane Rosefort; Ghada Fallah; Matthias U Kassack; Alexandra Hamacher; Mandy Bodnar; Haihong Wang; Peter Illes; Achim Kless; Gregor Bahrenberg; Günther Schmalzing; Ralf Hausmann
Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking.
Molecular pharmacology 2011;79(4):649-61.
2011: Peter C Kunz; Corinna Wetzel; Susanne Kögel; Matthias U Kassack; Bernhard Spingler
[(C3H4N2)2Au]Cl--a bis protic gold(I)-NHC.
Dalton transactions (Cambridge, England : 2003) 2011;40(1):35-7.
2010: Sabine Meis; Alexandra Hamacher; Darunee Hongwiset; Claudia Marzian; Michael Wiese; Niels Eckstein; Hans-Dieter Royer; Didier Communi; Jean-Marie Boeynaems; Ralf Hausmann; Günther Schmalzing; Matthias U Kassack
NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
The Journal of pharmacology and experimental therapeutics 2010;332(1):238-47.
2009: Peter C Kunz; Matthias U Kassack; Alexandra Hamacher; Bernhard Spingler
Imidazole-based phosphane gold(I) complexes as potential agents for cancer treatment: synthesis, structural studies and antitumour activity.
Dalton transactions (Cambridge, England : 2003) 2009;(37):7741-7.
2009: Niels Eckstein; Kati Servan; Barbara Hildebrandt; Anne Pölitz; Georg von Jonquières; Sybille Wolf-Kümmeth; Inge Napierski; Alexandra Hamacher; Matthias U Kassack; Jan Budczies; Manfred Beier; Manfred Dietel; Brigitte Royer-Pokora; Carsten Denkert; Hans-Dieter Royer
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Cancer research 2009;69(7):2996-3003.
2008: Elisabeth Christiansen; Christian Urban; Nicole Merten; Kathrin Liebscher; Kasper K Karlsen; Alexandra Hamacher; Andreas Spinrath; Andrew D Bond; Christel Drewke; Susanne Ullrich; Matthias U Kassack; Evi Kostenis; Trond Ulven
Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes.
Journal of medicinal chemistry 2008;51(22):7061-4.
2008: Eva M Gosepath; Niels Eckstein; Alexandra Hamacher; Kati Servan; Georg von Jonquieres; Hermann Lage; Balazs Györffy; hans-dieter royer; Matthias U Kassack
Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1.
International journal of cancer. Journal international du cancer 2008;123(9):2013-9.
2008: Mirko Magnone; Giovanna Basile; Debora Bruzzese; Lucrezia Guida; Maria Grazia Signorello; Madhu Parakkottil Chothi; Santina Bruzzone; Enrico Millo; Aidong Qi; Robert A Nicholas; Matthias U Kassack; Giuliana Leoncini; Elena Zocchi
Adenylic dinucleotides produced by CD38 are negative endogenous modulators of platelet aggregation.
The Journal of biological chemistry 2008;283(36):24460-8.
2008: Iliana Moreschi; Santina Bruzzone; Nicoletta Bodrato; Cesare Usai; Lucrezia Guida; Robert A Nicholas; Matthias U Kassack; Elena Zocchi; Antonio De Flora
NAADP+ is an agonist of the human P2Y11 purinergic receptor.
Cell calcium 2008;43(4):344-55.
2008: Niels Eckstein; Kati Servan; Luc Girard; Di Cai; Georg von Jonquieres; Ulrich Jaehde; Matthias U Kassack; Adi F Gazdar; John D Minna; hans-dieter royer
Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
The Journal of biological chemistry 2008;283(2):739-50.
2008: Reinhold Tacke; Friedrich Popp; Barbara Müller; Bastian Theis; Christian Burschka; Alexandra Hamacher; Matthias U Kassack; Dirk Schepmann; Bernhard Wünsch; Ulrik Jurva; Eric Wellner
Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate.
ChemMedChem 2008;3(1):152-64.
2008: Denise Ecke; Theodor Hanck; Mohan E Tulapurkar; Rainer Schäfer; Matthias U Kassack; Rolf Stricker; Georg Reiser
Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor.
The Biochemical journal 2008;409(1):107-16.
2007: Kathryn R Vaughan; Leanne Stokes; Lynne R Prince; Helen M Marriott; Sabine Meis; Matthias U Kassack; Colin D Bingle; Ian Sabroe; Annmarie Surprenant; Moira K B Whyte
Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(12):8544-53.
2007: Henrik Müller; Werner Klinkhammer; Christoph Globisch; Matthias U Kassack; Ilza K Pajeva; Michael Wiese
New functional assay of P-glycoprotein activity using Hoechst 33342.
Bioorganic & medicinal chemistry 2007;15(23):7470-9.
2007: Hendrik Greve; Sabine Meis; Matthias U Kassack; Stefan Kehraus; Anja Krick; Anthony D Wright; Gabriele M König
New iantherans from the marine sponge Ianthella quadrangulata: novel agonists of the P2Y(11) receptor.
Journal of medicinal chemistry 2007;50(23):5600-7.
2007: Johannes Trapp; Rene Meier; Darunee Hongwiset; Matthias U Kassack; Wolfgang Sippl; Manfred Jung
Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).
ChemMedChem 2007;2(10):1419-31.
2007: Jochen Zisowsky; Susanne Koegel; Stefan Leyers; Krishna Devarakonda; Matthias U Kassack; Maja Osmak; Ulrich Jaehde
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
Biochemical pharmacology 2007;73(2):298-307.
2006: Iliana Moreschi; Santina Bruzzone; Robert A Nicholas; Floriana Fruscione; Laura Sturla; Federica Benvenuto; Cesare Usai; Sabine Meis; Matthias U Kassack; Elena Zocchi; Antonio De Flora
Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes.
The Journal of biological chemistry 2006;281(42):31419-29.
2006: Ralf Hausmann; Jürgen Rettinger; Zoltan Gerevich; Sabine Meis; Matthias U Kassack; Peter Illes; Günter Lambrecht; Günther Schmalzing
The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups.
Molecular pharmacology 2006;69(6):2058-67.
2006: Barbara Hoefgen; Michael Decker; Patrick Mohr; Astrid M Schramm; Sherif A F Rostom; Hussein El-Subbagh; Peter M Schweikert; Dirk R Rudolf; Matthias U Kassack; Jochen Lehmann
Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist.
Journal of medicinal chemistry 2006;49(2):760-9.
2006: Alexandra Hamacher; Mathias Weigt; Michael Wiese; Barbara Hoefgen; Jochen Lehmann; Matthias U Kassack
Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.
BMC pharmacology 2006;6():11.
2005: Matthias U Kassack; C Stratenschulte
Expression profile of copper transporters in sensitive and cisplatin/oxaliplatin-resistant tumor cell lines.
International journal of clinical pharmacology and therapeutics 2005;43(12):597-8.
2005: E M Gosepath; S Weykam; Michael Wiese; Matthias U Kassack
Identification of new genes involved in cisplatin resistance and their expression profile in 18 human tumor cell lines.
International journal of clinical pharmacology and therapeutics 2005;43(12):579-80.
2005: Heiko Ullmann; Sabine Meis; Darunee Hongwiset; Claudia Marzian; Michael Wiese; Peter Nickel; David Communi; Jean-Marie Boeynaems; Christian Wolf; Ralf Hausmann; Günther Schmalzing; Matthias U Kassack
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
Journal of medicinal chemistry 2005;48(22):7040-8.
2005: Max Nunziante; Claudia Kehler; Elke Maas; Matthias U Kassack; Martin H Groschup; Hermann M Schätzl
Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
Journal of cell science 2005;118(Pt 21):4959-73.
2005: Ilse Wolner; Matthias U Kassack; Heiko Ullmann; Anton Karel; Martin Hohenegger
Use-dependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676.
British journal of pharmacology 2005;146(4):525-33.
2005: Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.
Naunyn-Schmiedeberg's archives of pharmacology 2005;372(1):1-13.
2005: Béatrice Hechler; Stéphanie Magnenat; Maddalena L Zighetti; Matthias U Kassack; Heiko Ullmann; Jean-Pierre Cazenave; Richard Evans; Marco Cattaneo; Christian Gachet
Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].
The Journal of pharmacology and experimental therapeutics 2005;314(1):232-43.
2005: Jürgen Rettinger; Kirsten Braun; Henrike Hochmann; Matthias U Kassack; Heiko Ullmann; Peter Nickel; Günther Schmalzing; Günter Lambrecht
Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist.
Neuropharmacology 2005;48(3):461-8.
2005: Veronika Jekerle; Matthias U Kassack; Raymond M Reilly; Michael Wiese; Micheline Piquette-Miller
Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques 2005;8(3):516-27.
2004: H Müller; Werner Klinkhammer; Matthias U Kassack; Niels Eckstein; Michael Wiese
Novel modulators to overcome P-glycoprotein-mediated multidrug resistance in tumor cells.
International journal of clinical pharmacology and therapeutics 2004;42(11):644-5.
2004: E M Gosepath; S Weykam; E Gruenewald; Y Ko; Michael Wiese; Matthias U Kassack
Differential gene expression studies in cisplatin-sensitive versus cisplatin-resistant human cancer cell lines.
International journal of clinical pharmacology and therapeutics 2004;42(11):637-9.
2004: Henrik Mueller; Matthias U Kassack; Michael Wiese
Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines.
Journal of biomolecular screening 2004;9(6):506-15.
2004: Daniel F McCain; Li Wu; Peter Nickel; Matthias U Kassack; Annett Kreimeyer; Antonio Gagliardi; Delwood C Collins; Zhong-Yin Zhang
Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases.
The Journal of biological chemistry 2004;279(15):14713-25.
2004: Matthias U Kassack; Kirsten Braun; Matthias Ganso; Heiko Ullmann; Peter Nickel; Barbara Böing; Gregor Müller; Günter Lambrecht
Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.
European journal of medicinal chemistry 2004;39(4):345-57.
2003: Jochen Zisowsky; Achim Becker; S Weykam; Matthias U Kassack; Ulrich Jaehde
Assessment of platinum sensitivity in human tumor cells.
International journal of clinical pharmacology and therapeutics 2003;41(12):612-3.
2003: Martin Hülsmann; Peter Nickel; Matthias U Kassack; Günther Schmalzing; Günter Lambrecht; Fritz Markwardt
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
European journal of pharmacology 2003;470(1-2):1-7.
2003: Matthias U Kassack
[Pharmacogenomics and gene expression analysis. Functional genome research for individual application to patients].
Medizinische Monatsschrift für Pharmazeuten 2003;26(5):165-6.
2003: Ursula Tammler; J Mark Quillan; Jochen Lehmann; Wolfgang Sadée; Matthias U Kassack
Design, synthesis, and biological evaluation of non-peptidic ligands at the Xenopus laevis skin-melanocortin receptor.
European journal of medicinal chemistry 2003;38(5):481-93.
2002: Matthias U Kassack; Barbara Höfgen; Michael Decker; Niels Eckstein; Jochen Lehmann
Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist.
Naunyn-Schmiedeberg's archives of pharmacology 2002;366(6):543-50.
2002: Ashraf H Abadi; Stefan Lankow; Barbara Hoefgen; Michael Decker; Matthias U Kassack; Jochen Lehmann
Dopamine/serotonin receptor ligands, part III [1]: synthesis and biological activities of 7, 7'-alkylene-bis-6, 7, 8, 9, 14, 15-hexahydro-5H-benz[d]indolo[2, 3-g]azecines -- application of the bivalent ligand approach to a novel type of dopamine receptor antagonist.
Archiv der Pharmazie 2002;335(8):367-73.
2002: Matthias U Kassack; Barbara Höfgen; Jochen Lehmann; Niels Eckstein; J Mark Quillan; Wolfgang Sadée
Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader.
Journal of biomolecular screening 2002;7(3):233-46.
2002: Siavosh Mahboobi; Steffen Teller; Herwig Pongratz; Harald Hufsky; Andreas Sellmer; Alexander Botzki; Andrea Uecker; Thomas Beckers; Silke Baasner; Christoph Schächtele; Florian Uberall; Matthias U Kassack; Stefan Dove; Frank-D Böhmer
Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.
Journal of medicinal chemistry 2002;45(5):1002-18.
2002: Matthias U Kassack
Quantitative comparison of functional screening by measuring intracellular Ca2+ with radioligand binding at recombinant human dopamine receptors.
AAPS pharmSci 2002;4(4):E31.
2002: Günter Lambrecht; Kirsten Braun; MiSusannechelle Damer; Matthias Ganso; Caren Hildebrandt; Heiko Ullmann; Matthias U Kassack; Peter Nickel
Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists.
Current pharmaceutical design 2002;8(26):2371-99.
2002: Oliver Kudlacek; Maria Waldhoer; Matthias U Kassack; Peter Nickel; Jussi I Salmi; Michael Freissmuth; Christian Nanoff
Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: the A1-adenosine receptor is predominantly coupled to Goalpha in human brain.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(1):8-16.
2001: Kirsten Braun; Jürgen Rettinger; Matthias Ganso; Matthias U Kassack; Caren Hildebrandt; Heiko Ullmann; Peter Nickel; Günther Schmalzing; Günter Lambrecht
NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.
Naunyn-Schmiedeberg's archives of pharmacology 2001;364(3):285-90.
2000: Matthias U Kassack; P Högger; D A Gschwend; K Kameyama; T Haga; RC Graul; Wolfgang Sadée
Molecular modeling of G-protein coupled receptor kinase 2: docking and biochemical evaluation of inhibitors.
AAPS pharmSci 2000;2(1):E2.
1999: M Klinger; Michael Freissmuth; Peter Nickel; M Stäbler-Schwarzbart; Matthias U Kassack; Josef Suko; Martin Hohenegger
Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site.
Molecular pharmacology 1999;55(3):462-72.
1998: Annett Kreimeyer; G Müller; Matthias U Kassack; Peter Nickel; Antonio Gagliardi
Suramin analogues with a 2-phenylbenzimidazole moiety as partial structure; potential anti HIV- and angiostatic drugs, 2: Sulfanilic acid-, benzenedisulfonic acid-, and naphthalenetrisulfonic acid analogues.
Archiv der Pharmazie 1998;331(3):97-103.
1998: Antonio Gagliardi; Matthias U Kassack; Annett Kreimeyer; G Muller; Peter Nickel; Delwood C Collins
Antiangiogenic and antiproliferative activity of suramin analogues.
Cancer chemotherapy and pharmacology 1998;41(2):117-24.
1996: Matthias U Kassack; Peter Nickel
Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues.
Journal of chromatography. B, Biomedical applications 1996;686(2):275-84.
1996: Matthias U Kassack; Peter Nickel
Stability of suramin in aqueous solution; possible implications for the search for suramin metabolites in patients.
Archiv der Pharmazie 1996;329(5):225-8.